SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dishman Pharmaceuticals gains as its arm receives EIR for two units

15 Jul 2016 Evaluate

Dishman Pharmaceuticals & Chemicals is currently trading at Rs 138.25, up by 1.40 points or 1.02% from its previous closing of Rs 136.85 on the BSE.

The scrip opened at Rs. 140.00 and has touched a high and low of Rs. 140.70 and Rs. 137.00 respectively. So far 164586 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 209.85 on 04-Nov-2015 and a 52 week low of Rs. 79.78 on 20-Jul-2015.

Last one week high and low of the scrip stood at Rs. 149.00 and Rs. 131.85 respectively. The current market cap of the company is Rs. 2250.64 crore.

The promoters holding in the company stood at 61.40%, while Institutions and Non-Institutions held 25.21% and 13.39% respectively.

Carbogen Amcis AG, a Switzerland based wholly owned subsidiary of Dishman Pharmaceuticals and Chemicals had successfully completed USFDA inspection for its two sites located at Aarau and Neuland without any adverse observations and received the Establishment inspection Report (ElR) for the same. Thus, now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA. Additionally, the company's site at Naroda had also successfully completed USFDA inspection and received the Establishment Inspection Report (ElR) for the same.

Dishman Pharmaceuticals and Chemicals is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×